TY - JOUR
T1 - Clinical Translation of Extracellular Vesicles
AU - Ghodasara, Aayushi
AU - Raza, Aun
AU - Wolfram, Joy
AU - Salomon, Carlos
AU - Popat, Amirali
N1 - Funding Information:
Partial funding was provided by the Medical Research Future Fund, Australia, under award MRF1199984 (CS), MRF1199984 (A.P.), and MRF2019485 (J.W.), The University of Queensland, Australia (C.S., J.W., A.P.), The Lion Medical Research Foundation (2015001964, C.S.), The Medical Research Future Fund (GA187319, C.S.), The Donald & Joan Wilson Foundation Ltd., (2020000323, C.S.), ovarian Cancer Research Foundation (OCRF, 2018001167, C.S.), and the National Health and Medical Research Council, Australia, under award NHMRC1195451 (C.S.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the organizations and funding agencies.
Publisher Copyright:
© 2023 The Authors. Advanced Healthcare Materials published by Wiley-VCH GmbH.
PY - 2023/7/8
Y1 - 2023/7/8
N2 - Extracellular vesicles (EVs) occur in a variety of bodily fluids and have gained recent attraction as natural materials due to their bioactive surfaces, internal cargo, and role in intercellular communication. EVs contain various biomolecules, including surface and cytoplasmic proteins; and nucleic acids that are often representative of the originating cells. EVs can transfer content to other cells, a process that is thought to be important for several biological processes, including immune responses, oncogenesis, and angiogenesis. An increased understanding of the underlying mechanisms of EV biogenesis, composition, and function has led to an exponential increase in preclinical and clinical assessment of EVs for biomedical applications, such as diagnostics and drug delivery. Bacterium-derived EV vaccines have been in clinical use for decades and a few EV-based diagnostic assays regulated under Clinical Laboratory Improvement Amendments have been approved for use in single laboratories. Though, EV-based products are yet to receive widespread clinical approval from national regulatory agencies such as the United States Food and Drug Administration (USFDA) and European Medicine Agency (EMA), many are in late-stage clinical trials. This perspective sheds light on the unique characteristics of EVs, highlighting current clinical trends, emerging applications, challenges and future perspectives of EVs in clinical use.
AB - Extracellular vesicles (EVs) occur in a variety of bodily fluids and have gained recent attraction as natural materials due to their bioactive surfaces, internal cargo, and role in intercellular communication. EVs contain various biomolecules, including surface and cytoplasmic proteins; and nucleic acids that are often representative of the originating cells. EVs can transfer content to other cells, a process that is thought to be important for several biological processes, including immune responses, oncogenesis, and angiogenesis. An increased understanding of the underlying mechanisms of EV biogenesis, composition, and function has led to an exponential increase in preclinical and clinical assessment of EVs for biomedical applications, such as diagnostics and drug delivery. Bacterium-derived EV vaccines have been in clinical use for decades and a few EV-based diagnostic assays regulated under Clinical Laboratory Improvement Amendments have been approved for use in single laboratories. Though, EV-based products are yet to receive widespread clinical approval from national regulatory agencies such as the United States Food and Drug Administration (USFDA) and European Medicine Agency (EMA), many are in late-stage clinical trials. This perspective sheds light on the unique characteristics of EVs, highlighting current clinical trends, emerging applications, challenges and future perspectives of EVs in clinical use.
KW - biomarkers
KW - clinical translation
KW - clinical trials
KW - drug delivery
KW - extracellular vesicles (EVs)
KW - liposomes
UR - http://www.scopus.com/inward/record.url?scp=85164470311&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85164470311&partnerID=8YFLogxK
U2 - 10.1002/adhm.202301010
DO - 10.1002/adhm.202301010
M3 - Article
C2 - 37421185
AN - SCOPUS:85164470311
SP - e2301010
JO - Advanced Healthcare Materials
JF - Advanced Healthcare Materials
SN - 2192-2640
ER -